렌티바이러스 벡터 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Lentiviral Vector Market Summary

The global lentiviral vector market size was valued at USD 601.1 million in 2025 and is projected to reach USD 1,140.6 million by 2033, growing at a CAGR of 8.4% from 2026 to 2033. Growth is driven by rising demand for gene and cell therapies, increasing clinical research, and advancements in vector manufacturing. However, high costs and regulatory complexities may hinder market expansion.

Global Lentiviral Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global lentiviral vector market report on the basis of product, indication, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• 1st-Generation
• 2nd-Generation
• 3rd-Generation
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• HIV
• B-Thalassemia
• X-Linked Adrenoleukodystrophy
• Metachromatic Leukodystrophy
• Wiskott-Aldrich Syndrome
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• CROs & CMOs
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Indication Segment
  • 1.2.3. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Lentiviral Vector Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growth of CAR-T and advanced immunotherapies
    • 3.2.1.2. Technological advancements in vector design
    • 3.2.1.3. Improved safety and efficiency of next-generation vectors
    • 3.2.1.4. Growing investment in biomanufacturing and CDMO capacity
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High production costs and scalability challenges
    • 3.2.2.2. Stringent regulatory requirements
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Case Study Insights
• 3.4. Lentiviral Vector Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTEL Analysis

Chapter 4. Lentiviral Vector Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Lentiviral Vector Market Product Movement Analysis
• 4.3. Global Lentiviral Vector Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. 1st-Generation
  • 4.4.1. 1st-generation market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. 2nd-Generation
  • 4.5.1. 2nd-generation market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. 3rd-Generation
  • 4.6.1. 3rd-generation market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Lentiviral Vector Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Lentiviral Vector Market Indication Movement Analysis
• 5.3. Global Lentiviral Vector Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 5.4. HIV
  • 5.4.1. HIV market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. B-Thalassemia
  • 5.5.1. B-thalassemia market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. X-Linked Adrenoleukodystrophy
  • 5.6.1. X-Linked adrenoleukodystrophy market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Metachromatic Leukodystrophy
  • 5.7.1. Metachromatic leukodystrophy market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Wiskott-Aldrich Syndrome
  • 5.8.1. Wiskott-aldrich syndrome market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Lentiviral Vector Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Lentiviral Vector Market End Use Movement Analysis
• 6.3. Global Lentiviral Vector Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical and Biotechnology Companies
  • 6.4.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & Research Institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. CROs & CMOs
  • 6.6.1. CROs & CMOs market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Lentiviral Vector Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Merck KGaA
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. OriGene Technologies Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. FinVector Oy
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Sino Biological Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Oxford Biomedica
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Lonza
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Vector Biolabs
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Takara Bio Inc.
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Sirion-Biotech GmbH (Revvity)
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives